2469 completed, 1117 unknown, 847 recruiting, 692 terminated. 6031 Phase 2, 1135 Phase 1, 402 Phase 3.
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp | Phase 2 | Not yet recruiting | Vejle Hospital | 110 | 2028-02-01 | 2026-04-30 |
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Oral Fosamprenavir for GERD Fosamprenavir Calcium 700 MG Oral Tablet, Placebo - Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 60 | 2027-10-01 | 2026-09-10 |
| Immunotherapy Treating GI Cancer engineered immune cells - Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| PET/MRI in Rectal Cancer Total Neo-adjuvant Therapy, 18FDG-PET/MRI scan - Rectal Cancer | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 40 | 2027-05-01 | 2026-10-28 |
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer Stereotactic body radiation treatment (SBRT) - Esophageal Cancer | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 22 | 2027-03-01 | 2026-10-28 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab - Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 184 | 2027-01-01 | 2026-07-10 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Alberta Cancer Exercise Dose in Colorectal Cancer Group Exercise Classes - Arm 1, Group Exercise Classes - Arm 2 - Cancer, Colorectal Cancer | Phase 2 | Not yet recruiting | University of Calgary | 90 | 2027-01-01 | 2026-11-03 |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 42 | 2026-12-15 | 2026-10-29 |
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-12-01 | 2026-10-05 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
Showing 20 of 6031. Sign in to see all of them.
Colorectal Neoplasms (1870) · Stomach Neoplasms (1083) · Rectal Neoplasms (714) · Esophageal Neoplasms (615) · Colonic Neoplasms (603) · Esophageal Squamous Cell Carcinoma (353) · Colitis, Ulcerative (345) · Crohn Disease (314) · Neoplasm Metastasis (298) · Neoplasms (246) · Carcinoma, Non-Small-Cell Lung (237) · Pancreatic Neoplasms (208) · Breast Neoplasms (184) · Inflammatory Bowel Diseases (168) · Gastrointestinal Neoplasms (160)
Digestive System Diseases (5990) · Digestive System Neoplasms (4421) · Neoplasms by Site (4377) · Neoplasms (4316) · Gastrointestinal Neoplasms (4288) · Intestinal Diseases (3712) · Colonic Diseases (2678) · Intestinal Neoplasms (2599) · Rectal Diseases (2428) · Stomach Diseases (1192) · Esophageal Diseases (1093) · Neoplasms by Histologic Type (994) · Gastroenteritis (945) · Head and Neck Neoplasms (922)
Oxaliplatin (652) · Fluorouracil (569) · Capecitabine (488) · Irinotecan (407) · Leucovorin (406) · Bevacizumab (368) · Cetuximab (274) · Cisplatin (272) · Radiotherapy (243) · Paclitaxel (212) · pembrolizumab (177) · Docetaxel (154) · Drug Therapy (137) · S 1 (combination) (135) · Nivolumab (123)
National Cancer Institute (NCI) (156) · Fudan University (113) · Sun Yat-sen University (104) · M.D. Anderson Cancer Center (72) · Memorial Sloan Kettering Cancer Center (66) · AstraZeneca (53) · Pfizer (47) · Eli Lilly and Company (44) · Hoffmann-La Roche (44) · Tianjin Medical University Cancer Institute and Hospital (44) · GlaxoSmithKline (42) · The First Affiliated Hospital with Nanjing Medical University (41) · Chinese Academy of Medical Sciences (40) · Amgen (38) · Mayo Clinic (38)
United States (2265) · China (1377) · France (509) · Canada (462) · Germany (447) · South Korea (432) · Spain (414) · United Kingdom (381) · Italy (375) · Belgium (312) · Japan (273) · Netherlands (273) · Australia (260) · Poland (260) · Taiwan (189)
Lin Shen, MD (10) · Norman Wolmark, MD (9) · Yelena Janjigian, MD (9)
PMID 35623069, PMID 15496622, PMID 28712102, PMID 37934000, PMID 40340830, PMID 22646630, PMID 26808342, PMID 32251400, PMID 33538338, PMID 38592721, PMID 26187751, PMID 26313683, PMID 26884585, PMID 27602924, PMID 28223062, PMID 30721964, PMID 31401903, PMID 32816630, PMID 35660797, PMID 36657089, PMID 36990609, PMID 40341124, PMID 40341199, PMID 40357993, PMID 41044356, PMID 14616164, PMID 15273542, PMID 15927411, PMID 16099600, PMID 16971718, PMID 17042060, PMID 17401014, PMID 17976611, PMID 18316791, PMID 19097774, PMID 19387663, PMID 20065174, PMID 20106720, PMID 20728210, PMID 20838998, PMID 21444866, PMID 21494121, PMID 21550216, PMID 21596621, PMID 21871249, PMID 22070868, PMID 22189752, PMID 22325170, PMID 22825365, PMID 23163616
2023 (66), 2017 (50), 2025 (43), 2018 (40), 2016 (39), 2019 (32), 2009 (31), 2015 (30), 2008 (29), 2014 (27), P30CA015083 (17), U10CA032102 (14), P30CA016672 (13), P30CA033572 (12), P30CA060553 (9)